Business Context and Reporting Period
Company: Bruker Corporation (BRKR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026 (Second Quarter)
Business Overview: Bruker develops, manufactures, and distributes high-performance scientific instruments and analytical/diagnostic solutions. The company operates through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST. Subsequent to the reporting period, the company reorganized its segments effective Q3 2026.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenue | $838.5 | $797.4 | $1,661.9 | $1,598.8 |
| Gross Profit | $416.0 | $357.9 | $795.8 | $749.1 |
| Gross Margin | 49.6% | 44.9% | 47.9% | 46.9% |
| Operating (Loss) Income | $(65.3) | $11.9 | $(55.1) | $43.7 |
| Net (Loss) Income (Common Shareholders) | $(62.9) | $7.6 | $(59.4) | $25.0 |
| Diluted EPS (Common) | $(0.41) | $0.05 | $(0.39) | $0.16 |
| Cash and Equivalents | $184.9 | $298.8 (Dec 31, 2025) | N/A | |
| Total Debt | $1,824.8 | $1,869.1 (Dec 31, 2025) | N/A | |
| Free Cash Flow (Non-GAAP, YTD) | $(59.2) | $(109.8) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5.2% in Q2 2026 and 3.9% YTD compared to the prior year. Growth was driven by foreign exchange tailwinds and recent acquisitions, particularly in the BSI CALID segment.
- Goodwill Impairment: A significant non-cash goodwill impairment charge of $134.9 million was recorded in Q2 2026. This consisted of $98.4 million related to the CST (formerly Automation) reporting unit and $36.5 million related to the BSB (Bruker Spatial Biology) reporting unit following a merger.
- Operating Loss: The company reported an operating loss of $65.3 million in Q2 2026, a reversal from the $11.9 million operating income in Q2 2025, primarily due to the goodwill impairment charges.
- Interest and Other Income: Net interest and other income improved significantly to $24.6 million in Q2 2026 (from $(11.4) million in Q2 2025), driven by a $27.6 million unrealized gain on an equity interest investment and a $12.2 million gain on the remeasurement of a previously held equity interest in Tofwerk.
- Segment Performance: BSI CALID revenue grew 8.6% in Q2, while BSI BioSpin and BSI NANO remained relatively flat. BEST revenue grew 11.9%.
Guidance, Outlook, and Risks
- Segment Reorganization: Effective Q3 2026, the company reorganized into new segments (BSI Biosystems, BSI Microbiology and Infection Diagnostics, BSI NANO, and BEST). This reorganization triggered an interim goodwill impairment analysis expected to be completed in Q3 2026, which may result in additional charges.
- Restructuring Plans: The company is executing multiple restructuring plans (Corporate-wide, BSI NANO, and BSI Biosystems) to drive cost efficiencies. The BSI Biosystems plan is estimated to cost between $12.0 million and $15.0 million.
- Tariff Impact: The company has submitted requests for refunds on tariffs paid under the IEEPA, with the majority approved as of June 30, 2026. However, ongoing global trade uncertainty and potential new tariffs remain a risk.
- Liquidity: Management anticipates existing cash and credit facilities will be sufficient for the next 12 months. The company has a $900 million Revolving Credit Facility with $729 million available as of June 30, 2026.
- Preferred Stock Dividends: The company paid $10.9 million in dividends on Series A Mandatory Convertible Preferred Stock in Q2 2026. These dividends are cumulative and payable quarterly.
Key Facts for Investor Verification
- Goodwill Impairment Sensitivity: Verify the assumptions used in the fair value analysis for the BSB reporting unit, as management noted a 100 basis point increase in the discount rate could reduce fair value by approximately 25%, potentially triggering further impairments.
- Q3 2026 Impairment Risk: Confirm the outcome of the interim goodwill impairment analysis required by the segment reorganization, which is expected to be finalized in Q3 2026.
- Acquisition Integration: Review the integration progress and revenue contribution of the Tofwerk acquisition (completed Jan 2026) and other recent acquisitions.
- Tariff Refund Status: Monitor the finalization of IEEPA tariff refund claims and the impact of any new trade policies on cost of revenue.
- Preferred Stock Conversion: Note that the Series A Mandatory Convertible Preferred Stock automatically converts to common stock on September 1, 2028, which will impact share count and EPS.